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Abstract
A novel technique is described for monitoring the in vivo behavior of gold nanorods (GNRs)
using γ -imaging. GNRs were radiolabeled using [125I] sodium iodide in a simple and fast
manner with high yield and without disturbing their optical properties. Radiolabeled GNRs
were successfully visualized by radioisotope tagging, allowing longitudinal in vivo studies to be
performed repeatedly in the same animal. The preliminary biodistribution study showed that
PEGylated GNRs have much longer blood circulation times and clear out faster, while bare
GNRs accumulate quickly in the liver after systematic administration. The highly efficient
method reported here provides an extensively useful tool for guidance of the design and
development of new gold nanoparticles as target-specific agents for both diagnostics and
photothermal therapy.
(Some figures in this article are in colour only in the electronic version)
1. Introduction
Nanoparticles, due to their small sizes and associated unique
properties, have been widely used in drug delivery [1–4],
cellular imaging [5–9], and biomedical diagnostics and
therapeutics [10–13]. Plasmonic gold nanostructures possess
intriguing physical and chemical properties which are
of interest for both fundamental science and biomedical
application [14]. Among the most fascinating and useful
are their optical properties as well as related photothermal
properties [15]. These optical properties depend on
nanoparticle size and shape [16, 17]. One can manipulate
the shape of gold nanostructures to control their electronic
and associated optical properties for different desired
applications [18, 19]. Their remarkable capacity to absorb
and scatter light in the visible and near-infrared (NIR)
regions is essential for optical imaging [20]. In addition,
gold nanoparticles can convert optical energy into heat
via nonradiative electron relaxation dynamics which endows
them with intense photothermal properties [21–24]. Such
localized heating effects can be directed toward the eradication
3 Author to whom any correspondence should be addressed.
of diseased tissue, providing a noninvasive alternative to
surgery [25]. Current nanotechnology research suggests that
gold nanoparticles form a novel class of optically active dual
imaging–therapeutic agents [26–28].
In particular, gold nanorods (GNRs) have attracted much
interest because of their small size, ease of preparation and
bioconjugation, strong absorbing and scattering properties, as
well as their well-known biocompatibility [14, 20, 29, 30].
GNRs with well-defined shapes and sizes are readily
synthesized by seeded growth methods, and their longitudinal
plasmon resonances (LPRs) can be finely tuned as a function
of aspect ratio [14, 29, 31]. GNRs support a larger absorption
cross-section at NIR frequencies per unit volume than most
other nanostructures and have narrower line widths due to
reduced radiative damping effects with consequently higher
optothermal conversion efficiencies [20, 21, 32]. The LPRs
can also support nonlinear optical effects, such as plasmon-
enhanced two-photon luminescence (TPL) [20, 33]. The LPRs
are also sensitive to the polarization of the incident excitation;
by slightly adjusting the wavelength of a continuous-wave (cw)
polarized laser, individual GNRs can be aligned for several
minutes in an optical trap [34]. These properties give rise to
many exciting possibilities for deploying GNRs for biological
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imaging and photothermal therapy [20]. Furthermore, the
surface chemistry of GNRs allows multiple functionalizations.
Capping molecules, such as cetyltrimethylammonium bromide
(CTAB), can be replaced or conjugated with many functional
groups [35–37]. Target specificity of GNRs can be imparted
by tagging with certain biovectors, such as monoclonal
antibodies [38], receptor-specific peptides [14], and other
compounds [20, 39], which can navigate them to desired
organs or sites. Recent studies have successfully demonstrated
that GNRs with strong near-IR absorption can be conjugated
to molecules to facilitate delivery to the tumor for subsequent
efficient cancer cell diagnostics and selective photothermal
therapy simultaneously [14, 30, 38].
In addition, the technique of introducing polyethylene
glycol (PEG) to the surface of nanoparticles allow steric
stabilization of particles. PEG can shield nanoparticles
from fouling by serum proteins and reduce the adsorption
of reticuloendothelial system (RES) factors in the blood on
the particle surface. This reduces the rate of clearance of
particles by cells of the monophagocytic system and creates
long-circulating particles which hold the promise of in vivo
utilization of nanoparticles.
To advance GNRs toward realistic clinical applications
and to optimize their diagnostic sensitivity, payload, or
therapeutic efficiency, it is becoming urgent to understand
how they interact with biological systems. Various in vitro
studies have provided fundamental information as to how
nanoparticle size and surface chemistry greatly affect their
interaction with plasma proteins, cellular uptake, toxicity, and
molecular response. However, the in vivo environment is
far more complex than in vitro model systems [38–41]. For
instance, blood contains a variety of ions such as hydrogen,
Na, Cl, Ca, etc, as well as proteins, lipids, hydrocarbons, and
other components that may affect nanoparticle stability and
functionality [38]. Studying the stability and functionality of
injected GNRs within the in vivo environment is technically
challenging.
Recently, there has been increasing use of radioisotopes
to study nanoparticles because of the availability of
highly sensitive methods to detect radioactivity. In most
cases, a bifunctional group, like 1,4,7,10-tetraazadodecane-
N,N ′,N ′′,N ′′′-tetraacetic acid (DOTA), has to be conjugated
to the nanoparticle and then a radioactive metal needs to
be attached. This requires modification of nanoparticles
before radiolabeling. The study we report here is an initial
investigation of the in vivo behavior of [125I]-iodine-labeled
GNRs, which uses I-125 to directly label GNRs. It has
been proven that iodide ions show high affinity and strong
binding to the surface of GNRs [44–46]. [125I]-iodine
should be easily tagged onto GNRs by simple mixing. The
labeling method developed here can be adapted to 123I, 124I,
and 131I for more extensive applications. The stability and
metabolism pattern of radiolabeled GNRs in normal rats were
successfully examined using γ -scintigraphy. Longitudinal
biodistribution studies have been performed repeatedly in the
same animal for up to 6 days, therefore decreasing sources
of inter-individual variation while being efficient in terms of
animal cost and ethical practice. Radiolabeling of GNRs
allows systematic study of gold nanoparticles within in vitro
and in vivo microenvironments, providing a highly efficient
methodology for bioevaluation of different kinds of GNRs
and their bioconjugates. The novel protocol reported here
could be extensively useful for guidance of the design and the
development of new target-specific gold nanoparticles.
2. Materials and methods
2.1. Materials
[125I]radionuclide in 10−5 M NaOH (pH 8–11) was purchased
from PerkinElmer with a specific activity of 100 mCi ml−1.
Fresh deionized water was used to dilute [125I]NaI to the
activity desired, around 3 mCi ml−1 for animal studies.
Chemicals and solvents were purchased from Sigma-Aldrich
(Milwaukee, WI, USA) or Fisher Scientific (Fair Lawn, NJ,
USA) and used without further purification.
2.2. Synthesis of PEGylated GNRs
GNRs with an average aspect ratio of 4, capped with
hexadecyltrimethyl ammonium bromide were synthesized
using the seed-mediated growth methods reported in the
literature [42, 43]. After synthesis, gold nanorods were
centrifuged and re-dispersed in deionized water to a final
concentration of 1012 rods ml−1. Polyethylene glycol (PEG)
thiol molecules were dispersed in deionized water (1 ml,
50 mg ml−1) and mixed with GNRs (1 ml, 1012 rods ml−1).
The mixture was allowed to react overnight, followed by
centrifugation and re-dispersion of rods to a final concentration
of 1012 rods ml−1. The zeta potential of bare GNRs is +40 mV
and after PEGylation is reduced to +8 mV (5000 mol. wt) and
+10 mV (20 000 mol. wt)
2.3. Radiolabeling of GNRs
In general, 0.1 ml of GNRs with a concentration of
1012 rods ml−1 in deionized water was placed into a
polypropylene microcentrifuge tube (1.5 ml) and 0.5 ml of
diluted [125I]NaI was added, roughly 300 μCi of radioactivity.
The vial was rotated on a ROTAMIX rotater (Appropriate
Technical Resources, Inc. Laurel, MD, USA). The mixture
was then centrifuged at 5000 rpm using a Beckman Microfuge
II. The supernatant was decanted and pellets were re-dispersed
in 0.1 ml of fresh sterile filtered deionized water. Various
reaction times of 2, 10, 20, and 30 min were tested, as well
as various centrifugation periods of 5, 10, 15, and 30 min.
The optical absorption spectra of diluted GNRs in saline
solution were measured before and after radiolabeling by using
a spectrophotometer (PerkinElmer, MA, USA) with the sample
contained in a 1 cm pathlength plastic cuvette. GNRs were also
imaged by transmission electron microscopy (TEM).
2.4. Stability of GNRs in the blood circulation
Male Sprague Dawley rats (∼250 g) were purchased from
Charles River Laboratories (Wilmington, MA, USA). The rats
were anesthetized using an isoflurane anesthesia machine. Two
2
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Figure 1. UV–vis spectra of GNRs before and after labeling with
I-125.
I.V. catheters were placed into lateral tail veins separately, one
for injection of the 125I-GNR dose and another for extraction
of blood samples. The catheters were rinsed with 0.2 ml of
saline after injection and every extraction. 125I-labeled GNRs
prepared as mentioned above were injected into rats through
a tail vein, 100–130 μCi in 0.1 ml of water for each animal.
Three rats were used for each kind of GNR. Blood samples
(0.1 ml) were collected from another tail vein at set times, from
1 min to 4 h post-injection. Radioactivity in each blood sample
was counted using a γ -counter (MINAXI Auto-gamma 5000
series, Packard Instrument Co., Grove, IL, USA).
2.5. Long-term biodistribution using γ -imaging
The same group of animals used for blood assays were imaged
at set times between blood sampling. After the measurements
on day 1, the animals were re-anesthetized and scanned once
each day from day 2 to day 6 before they were sacrificed. Each
image was acquired in 5 min on an anesthetized rat placed in
an anterior position over the parallel-hole collimator 1.8/0.2/20
(hole diameter/septum thickness/height in mm) of a Gamma
Imager (Biospace Lab, Paris, France). Radioactivity was then
quantified by drawing regions of interest (ROIs) using Gamma
Vision+ software (Version 3.0). For each animal, ROIs were
drawn around the liver/spleen and heart/lung and were saved to
be re-used systematically for longitudinal follow-up.
3. Results
3.1. Preparation of 125I-labeled GNRs
GNRs, either bare or PEGylated, were radiolabeled by
mixing with [125I] sodium iodide in deionized water at room
temperature. The reaction takes place very rapidly and
completely, with a radiochemical yield greater than 90% by
radioactivity count and specific activity greater than 5 ×
105 Ci mmol−1. No differences in yield or specific activity
were noticed between bare GNRs and PEGylated GNRs. There
were no significant differences observed when the mixtures of




(% from total, n = 12)
Aggregation
(%) n = 12
5 60.0 ± 6.1 0
10 74.4 ± 3.3 0
15 90.0 ± 3.1 0
30 99.4 ± 0.6 33.3
[125I] sodium iodide and GNRs were mixed for 2, 10, 20, or
30 min prior to centrifugation. This agrees well with the prior
reports of high affinity and strong binding of iodide ions to
the surface of GNRs [44–46]. It has previously been reported
that iodide ions may affect the shape and size of GNRs [45].
In our case, the concentration of iodide is extremely low and
has no significant impact on the optical property of the GNRs.
Figure 1 shows the absorption spectra of GNRs measured
before and after radiolabeling in a wavelength range from
400 to 1000 nm. Both transverse and longitudinal plasmon
peaks remain unchanged in intensity after radiolabeling but
show a small plasmon shift due to the presence of additional
iodine molecules on the surface. [125I]-iodine-labeled GNRs
are stable for weeks when stored in a refrigerator.
The transmission electron microscopy (TEM) images
are shown in figure 2. The shape and size of the GNRs
remains unchanged before and after radiolabeling. There
are no differences observed between bare, 5, and 20 K
PEGylated GNRs.
The washing process using centrifugation is critical.
Uncompleted centrifugation causes a loss of radioactive
GNRs in decanted supernatant, resulting in low radiochemical
yields. On the other hand, the chance of irreversible
nanorod aggregation increases when the centrifugation period
is extended. A series of experiments were performed
to investigate and optimize the conditions. To minimize
variations, radiolabeled GNRs were initially washed twice
to remove free radioactive iodide and then dispersed in
deionized water. Table 1 summarizes the percentage of
radioactivity collected in pellets after centrifugation for various
time periods. It should be noticed that a centrifugation time of
30 min at 5000 rpm is necessary to recover all GNRs. However,
the possibility of failure to deliver the desired product would
then be over 30% due to irreversible nanorod aggregation.
Therefore, one washing using 15 min centrifugation was
applied for subsequent animal studies. No further washing will
be needed due to the high affinity of iodide ions to GNRs.
In summary, injectable doses for animal studies were
prepared by mixing 0.5 ml of [125I] sodium iodide with the
desired activity and 0.1 ml of GNRs (1012 rods ml−1) for 5 min,
and then centrifuging at 5000 rpm for 15 min. The supernatant
was decanted and pellets were re-dispersed in 0.1 ml of fresh
sterile filtered deionized water. The same procedure was
applied for bare, 5, and 20 K PEGylated GNRs.
3.2. Stability of GNRs in the blood circulation
To determine the circulating time of GNRs, we assayed blood
samples from rats (n = 3 for each kind of GNR) using γ -
scintigraphy. The time–activity curves are shown in figure 3,
3
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Figure 2. TEM images of bare GNRs (a), bare GNRs with I-125 (b), PEGylated GNRs (c) and PEGylated GNRs with I-125 (d).
Figure 3. Blood time–activity curves.
and indicate significant differences between bare GNRs and
PEGylated GNRs. Injected bare GNRs were cleared out from
the blood circulation within 10 min, while more than 50% of
PEG coated GNRs remained in the blood after 4 h. This is
in good agreement with previous studies which have shown
that a surface brush layer of PEG reduces the adsorption of
blood RES factors to the particle surface, hence decreasing the
rate of particle clearance [40, 48]. We have also found that it
is irrelevant whether a molecular weight of 5000 or 20 000 is
used.
3.3. Long-term biodistribution using γ -imaging
The next experiment evaluated the relatively long-term
biodistribution in rats for up to 6 days using γ -imaging. The
same group of animals (n = 3 for each kind of GNR) used for
blood assays were imaged at set times between blood sampling.
Each image was acquired in 5 min on an anesthetized rat
placed in an anterior position over the parallel-hole collimator
of a Gamma Imager. Radioactivity was then quantified by
drawing ROIs. For each animal, ROIs were drawn around
the liver/spleen and heart/lung and were saved to be re-used
systematically for longitudinal follow-up. Figure 4 shows
typical rat gamma images.
The linearity and precision of gamma detection were
determined by scanning a series of standards with known
radioactivities. The standards were prepared by serial dilution
of a 125I-GNR injection sample. To obtain the average and the
standard deviation, each standard was imaged eight times in
various positions over the parallel-hole collimator, each taking
5 min for acquisition. Radioactivity was then quantified by
drawing ROIs around the standard. Figure 5 shows good
correlation between radioactivities counted by a Capintec and
radioactivities measured by scintigraphic acquisition of the
Gamma Imager. The coefficient of determination (R2 value)
was greater than 0.99. The exact position of the sample on the
camera head was shown to be irrelevant.
Radioactivities in liver/spleen and heart/lung determined
by the Gamma Imager were converted to injection dose based
on this standard curve. The uptakes of liver/spleen and
heart/lung were then normalized to a percentage of the injected
dose for each animal. Results are shown in figure 6.
Uncoated bare GNRs were found to accumulate quickly
in the liver and spleen area within 5 min. It should be noted
that, for bare GNRs, radioactivity was retained in the liver
and spleen for days. The radioactivity well represented the
4





Figure 4. Gamma images at different post-injection times (5 min, 4 h, and 6 days). The upper three images are from a rat injected with
PEGylated GNRs. The lower three images are from a rat injected with bare GNRs.
Figure 5. 125I-GNR standard curve.
concentration of GNRs because any disassociated 125I should
be collected in the thyroid. In contrast, PEG coated GNRs
remained in the blood pool for a much longer period, but the
long-term accumulation was minimal in the liver and spleen.
All animals were sacrificed at day 6 and examined. There
was no apparent damage observed in heart, lung, and liver.
Thyroids of all animals had radioactivity as expected. PEG
coated GNRs gave a higher thyroid uptake, while bare rods had
been trapped in liver tissue from an earlier time point and not
much free iodide got into thyroid tissue. To keep all animals
in the same condition, we did not pre-treat any rats with cold
iodine to block the thyroid in this experiment.
4. Discussion
To date, there have been no previously reported in vivo
animal studies using 125I-labeled GNRs. We have optimized
Figure 6. Activities in liver/spleen and heart/lung versus time.
the radiolabeling procedures, facilitating the reproducible and
reliable production of injectable doses for animal studies.
GNRs were successfully visualized by a 125I tag allowing
5
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highly sensitive detection. This simple setup can be further
developed to deliver injectable doses for clinical application.
The stability of injected GNRs within the body is a key
issue for successful targeting of GNRs because they must
be able to circulate in the blood for long enough to find
their targets [38]. However, the RES filters nanoparticles
from the blood circulation based on their size and surface
characteristics [20, 40]. Rapid clearance of nanoparticles
from blood limits their targeting capabilities. PEG has well-
established ‘stealth’ properties that can shield nanoparticles
from fouling by serum proteins (opsonization) and reduce their
rate of clearance by the RES [20, 36]. The beneficial effects
of PEGylation on the clearance time of injected nanoparticles
have been demonstrated [38, 47]. Therefore, we synthesized
three different kinds of GNRs, normal bare GNR, PEGylated
GNR with PEG 5000 (mw), and PEG 20 000, and examined
their stabilities in the blood circulation. The preliminary
animal results are very promising. Significant differences
between bare GNRs and PEGylated GNRs have been observed
with a minimum number of animals used (figure 3). PEG
coated GNRs remained in the blood for much longer than bare
GNRs. This provided evidence that a surface brush layer of
PEG reduces the adsorption of blood RES factors to the particle
surface, hence decreasing the rate of particle clearance [40, 48].
The blood assay method described above is easy and reliable,
providing initial information about novel GNRs in biological
systems. γ -Scintigraphy is highly sensitive. Only a low dose
of radioactivity has to be administrated and a small amount of
blood needs to be drawn for measurement. This simple assay
would be the first step for screening any newly designed target-
specific GNRs.
The linearity and precision of the Gamma Imager
were tested by scanning a series of standards with known
radioactivities. The coefficient of determination (R2 value)
was greater than 0.99 (figure 5), indicating accurate and
reliable measurement. For long-term biodistribution studies,
the liver/spleen and heart/lung areas were chosen as ROIs
because GNR particles accumulate in the liver and spleen when
they are removed from the blood; while they can be seen
in the heart and lung when they are still freely circulating
in the blood. Figure 6 shows the significant differences in
uptakes between bare GNRs and PEGylated GNRs, and more
importantly, the distinct pattern of metabolism. The bare
GNRs were retained in the liver and spleen for days. This
indicates that bare metal particles are cleared from the body
with difficulty. In contrast, PEG coated GNRs remained in the
blood pool for much longer, but the long-term accumulation
was minimal in liver and spleen. For both the measurements
from the heart/lung and liver/spleen areas there is no noticeable
difference between the results from the GNRs coated with
PEG 5000 and PEG 20 000. The observed efficient metabolic
clearance pattern provides evidence that PEGylated GNRs are
more biocompatible within the body. They are hence ideal
candidates for target-specific dual agents for diagnostics and
selective photothermal therapy. The trends described here need
to be tested in more detail with a wider range of GNRs and
will be reported in due course. This methodology provides a
highly efficient tool for monitoring in vivo behaviors of gold
nanoparticles.
In addition, we have successfully utilized GNRs
to enhance the contrast in photoacoustic tomography
(PAT) [31]. We expect that radioisotope-labeled GNRs can
lead to the development of dual-modality imaging with a
combination of nuclear imaging modalities, like single photon
emission computed tomography (SPECT) or positron emission
tomography (PET), and PAT. Furthermore, it is hoped that
radiolabeled GNRs will become an efficient therapeutic agent
combining the power of radiation therapy and photothermal
therapy.
5. Conclusion
PEGylated GNRs are ideal candidates for target-specific dual
agents for diagnostics and selective photothermal therapy.
The methodology developed here should provide a highly
efficient protocol for monitoring in vivo behaviors of gold
nanoparticles. Longitudinal biodistribution studies have been
performed repeatedly in the same animal, therefore decreasing
sources of inter-individual variations and also being beneficial
in terms of animal cost and ethical practice. With this
powerful tool in hand, more work can be done to advance GNR
technology to a level for clinical use with regard to clearance,
safety, efficacy of delivery, and targeting. Encouraged by
the preliminary study reported here, further investigations of
GNRs of various sizes, shapes, and different conjugates are
being investigated. Radiolabeled GNRs hold promise to enable
the development of multifunctional nanomedical platforms for
simultaneous targeting, imaging, and therapy administration.
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